Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Companies are racing to develop alternatives to injectable diabetes and weight loss drugs Injectable peptide drugs targeting the glucagon-like peptide 1 (GLP-1) receptor have had massive impact on approaches to treating diabetes and obesity, bringing huge revenue boosts to makers Novo Nordisk and Eli Lilly
E.JeonJ
Metabolic Control
Members with type 2 diabetes may need support to understand how GLP-1s might fit into their personal treatment plan and what to expect when taking this type of treatment
US$ 28.15
US$ 21.32
US$ 23.82
US$ 27.10
US$ 25.95
